Duramed and estrogens
Executive Summary
FDA refuses generic firm's request for an indefinite extension of the June 15 deadline for replies to the agency's proposed withdrawal of all ANDAs for generic conjugated estrogens on June 12. Duramed had sought the extension in a June 4 petition in which it alleged that FDA's May 4 ad hoc subcommittee on conjugated estrogens meeting was prejudiced by several panel members with conflicts of interest.
You may also be interested in...
Clinical Trial Diversity Requires Sponsors Work With An Assortment Of Patient Advocates, Community Organizations
US FDA oncology officials are concerned that the entities sponsors are consulting in developing and implementing clinical trial diversity plans are not sufficiently diverse themselves and do not represent patients in underserved communities.
Israeli Company Lands De Novo Clearance For Digital Bone Marrow Application
The US FDA has cleared a novel software application to enhance the analysis of bone marrow smears. Using the AI-powered tool, hematopathologists may be able to better diagnose various blood and marrow diseases.
Marinomed Takes Virus-Blocking Device Into Allergy And Dry Eye Categories
Virus-blocking compound Carragelose, out-licensed to major consumer health players such as Perrigo and Reckitt for use in OTC respiratory nasal sprays, is being adapted for use in the dry eye and allergy categories.